Fluidra S.A. (0ILI)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 18.01 |
|---|---|
| 52-week range | 16.92 – 26.16 |
| Return, 1 month / 3 months | −0.7% / +0.2% |
| Return, 1 year / 3 years | −21.6% / +17.5% |
| Trend | Below its 200-day average |
| RSI (14) | 55 |
| Volatility (1 year) | 26.4% |
| Worst drawdown (1 year) | -33.5% |
| Average daily value traded | 1.42M EUR |
| Dividend yield | 2.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Fluidra is a Spanish manufacturer of equipment for pools and wellness installations, based near Barcelona. It makes and supplies products such as pumps, filters, water treatment systems, lighting and cleaning equipment for residential and commercial pools, along with components for spa and water features. Its customers include pool builders, installers, distributors and facility operators, and it serves markets in many countries through its own brands and distribution networks.
On this site Fluidra S.A. appears as a stock on the London Exchange (UK), code 0ILI, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Fluidra S.A. (0ILI) trades on the London Exchange in UK. It last closed at EUR 18.01 on 23 October 2026.
Its price-based Market X-Ray is 44 out of 100 (a weak price profile), ranking 2,387 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 21.6% and over the last three months it rose 0.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 26 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -10.2% | ||
| From 52-week high | -30.6% | ||
| Momentum | 34 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 0.2% | ||
| 6-month return | -13.0% | ||
| 12-month return, skipping the last month | -21.1% | ||
| Stability (higher is calmer) | 57 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 26.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -33.5% | ||
| Liquidity | 57 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.42M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 66 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 2.8% | ||
| Years with dividends | 6 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +1.9% |
|---|---|
| 1 month | −0.7% |
| 3 months | +0.2% |
| 6 months | −13.0% |
| 1 year | −21.6% |
| 3 years | +17.5% |
| 5 years | −44.1% |
Signals
| 50-day / 200-day average | 18.24 / 20.05 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.92 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 10 Jul 2026 | EUR 0.2592 |
| 1 Dec 2025 | EUR 0.2430 |
| 30 Jun 2025 | EUR 0.2430 |
| 29 Nov 2024 | EUR 0.2025 |
| 1 Jul 2024 | EUR 0.2430 |
| 1 Dec 2023 | EUR 0.2835 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.